Invenra’s Bispecific B-Body® Platform and Trispecific T-Body™ Platform: Versatile Multispecific Systems for Broad-Spectrum ADC Discovery
- Invenra’s proprietary B-Body and T-Body multispecific platforms were built for rapid, in-format discovery as well as for simple manufacturing.
- We combine two multispecific platforms to provide a rapid screening system to empirically identify optimal bispecific and trispecific ADC target combinations.
- We describe the generation of a 12×12 matrix of bispecific B-Body antibodies targeting 6 antigens to identify optimal pairs for trispecific T-Body ADCs for breast cancer.
- Our approach highlights two powerful platforms for next-generation ADCs, offering promise for more effective and versatile breast cancer therapies.